Compare Citius Pharmaceuticals Inc (CTXR) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while SYSCO Corporation trades at $84.73 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 2015× Citius Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SYY | |
|---|---|---|
Market Cap | $20.01M | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $91.16 |
52-Week Low | $0.48 | $69.30 |
Enterprise Value | $16.23M | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
SYY trades at $85.24, up 1.63% with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings of $1.53 EPS, beating estimates, with revenue growth to $81.37B in 2025. Analyst consensus is bullish with 60% buy ratings and an $88.25 price target. Recent news highlights CEO discussions on CNBC and positive earnings coverage.
Outlook remains positive with steady revenue growth and efficiency initiatives driving margins. Risks include competitive pressures and macroeconomic uncertainty. The stock offers value with a P/S of 0.48 and dividend yield support, but high P/B of 15.12 warrants caution on valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
